摘要:美国医药巨头强生近日宣布,评估降糖药Invokana(canagliflozin,卡格列净)肾脏预后的III期临床研究因疗效特别显著已提前终止——因为数据显示,Invokana有望成为过去15年来首个可延缓2型糖尿病患者肾脏病进展的新药。在2型糖尿病患者中,几乎有一半的人会发展成慢性肾脏病,并增加患者出现肾衰竭和心血管疾病的风险.
注:因版权方要求,不能公开全文,如需全文,请咨询杂志社
热门期刊服务
China Ocean Engineering Journal of Bionic Engineering Earthquake Engineering and Engineering Vibration Chinese Journal of Mechanical Engineering Water Science and Engineering Frontiers of Information Technology Electronic Engineering Chinese Journal of Chemical Engineering International Journal of Computing Journal of Integrative Agriculture International Journal of Oral Science Journal of Beijing Institute of Technology Journal of Systems Engineering and Electronics